Translational Investigations of Pulmonary and Immunological Diseases – ZRG1 RCCS (81)

Topics

• Human clinical trials generally centered upon mechanisms and consequences of respiratory conditions and diseases, including pediatric populations. Investigations may involve respiratory imaging and may include physiology, pharmacology, electrophysiology, respiratory mechanics, biomarker discovery, and genetics/omics studies.
• Human clinical trials investigating autoimmune diseases, immunological mechanisms and responses in the context of transplantation, and immune-mediated diseases including hypersensitivities and allergies.
• Clinical and pre-clinical studies involving assessment of immune and pulmonary responses to pharmacologic or biologic interventions or challenges.
• Biomarker discovery, development and/or validation for use in wide-ranging studies, including utility in tracking disease/therapeutic progression, and responses in human and pre-clinical populations.
• Identification of molecular phenotypes/endotypes in human populations by integration of multiomics studies for interventional, observational or use of Electronic Medical Record (EMR).
• Longitudinal studies examining disease initiation, exacerbation, or progression of respiratory or immunological conditions or diseases.
• Preclinical efficacy studies leading to clinical trials for therapeutics, diagnostics, including new devices.

Shared Interests and Overlaps

There are shared interests with Lung Immunology and Infection (LII) and Pulmonary Vascular Disease and Physiology (PVP) regarding pulmonary diseases. While LII may review basic and physiological topics related to aspects of lung immunology and infection, those which propose clinical trials may be reviewed in RCCS (81). While PVP will evaluate basic or physiological topics related to vascular conditions and diseases, studies which are patient-oriented and/or include clinical trials may be reviewed in RCCS (81).

There are shared interests with Pulmonary Injury Remodeling and Repair (PIRR) regarding pulmonary diseases. While PIRR will evaluate basic or physiological topics in the lung, applications which propose to create novel experimental systems to model human lung diseases may be reviewed in RCCS (81).

There are shared interests with Mechanisms of Autoimmunity (MAI). Applications that address immunological mechanisms of failed self-tolerance in the context of autoimmunity that use human and/or animal models as well as in vitro systems, molecular, cellular, genomic and proteomic approaches may be reviewed in MAI. Translational research that uses study cohorts and clinical trial platforms to examine strategies to prevent and/or ameliorate autoimmune disease may be reviewed in RCCS (81). 

There are shared interests with the Immune Mechanisms of Hypersensitivity and Allergy (IMHA). Applications investigating molecular and cellular mechanisms associated with allergy and hypersensitivities involving animal models, human specimens and/or data, or studies with human participantsthat do not meet the definition of a clinical trial may be reviewed in IMHA. Applications that propose preclinical translational research and clinical trials, including those focusing on interventions which investigate immune-mediated disorders such as hypersensitivities and allergy may be reviewed by RCCS (81). 

There are shared interests with Immunobiology of Transplantation and Alloimmunity (ITA). Applications which involve animal models, human specimens and/or data, or studies with human participants that do not meet the definition of a clinical trial to study the immunology of transplantation such as the mechanisms that lead to tolerance or rejection may be reviewed in ITA. Applications that propose preclinical translational research and clinical trials, including those focusing on interventions in the context of transplantation, may be reviewed in RCCS (81). 

There are shared interests in respiratory conditions with Cardiovascular and Respiratory Diseases (CRD). Applications which emphasize the distribution and determinants of respiratory diseases conditions in human subpopulations with an epidemiological approach may be reviewed in CRD, whereas applications that use a more patient-oriented approach to study pulmonary diseases may be reviewed in RCCS (81). 

There are shared interests with Clinical Data Management and Analysis (CDMA) regarding the topic of electronic medical records (EMR). Applications which propose to generate EMR may be reviewed in CDMA, whereas the use of EMR to generate patient or disease profiles associated with respiratory or immune-related conditions may be reviewed in RCCS (81).